Guillaumier Stephanie, Solomon Eskinder, Jenks Julie, Pakzad Mahreen, Hamid Rizwan, Ockrim Jeremy, Shah Julian, Greenwell Tamsin
Department of Urology, University College London Hospital, London, W1G 8PH, UK.
Urol Ann. 2017 Jul-Sep;9(3):253-256. doi: 10.4103/UA.UA_25_17.
The objective of this study is to present the outcomes of men undergoing implantation of artificial urinary sphincter, after treatment for prostate cancer and also to determine the effect of radiotherapy on continence outcomes after artificial urinary sphincter (AUS) implantation.
A prospectively acquired database of all 184 patients having AUS insertion between 2002 and 2012 was reviewed, and demographic data, mode of prostate cancer treatment(s) before implantation, and outcome in terms of complete continence (pad free, leak free) were assessed. Statistical analysis was performed by Chi-squared and Fisher's exact tests.
A total of 58 (32%) men had bulbar AUS for urodynamically proven stress urinary incontinence consequent to treatment for prostate cancer in this period. Median follow-up post-AUS activation was 19 months (1-119). Forty-eight (83%) men had primary AUS insertion. Twenty-one (36%) men had radiotherapy as part of or as their sole treatment. Success rates were significantly higher in nonirradiated men having primary sphincter (89%) than in irradiated men (56%). Success rates were worse for men having revision AUS (40%), especially in irradiated men (33%).
Radiotherapy as a treatment for prostate cancer was associated with significantly lower complete continence rates following AUS implantation.
本研究的目的是介绍前列腺癌治疗后接受人工尿道括约肌植入术的男性患者的治疗结果,并确定放疗对人工尿道括约肌(AUS)植入术后控尿结果的影响。
回顾了一个前瞻性收集的数据库,该数据库包含2002年至2012年间所有184例接受AUS植入术的患者,评估了人口统计学数据、植入前前列腺癌的治疗方式以及完全控尿(无尿垫、无漏尿)方面的结果。采用卡方检验和Fisher精确检验进行统计分析。
在此期间,共有58名(32%)男性因前列腺癌治疗导致尿动力学证实的压力性尿失禁而接受了球部AUS植入术。AUS激活后的中位随访时间为19个月(1 - 119个月)。48名(83%)男性首次植入AUS。21名(36%)男性接受了放疗,作为其部分治疗或唯一治疗。首次植入括约肌的未接受放疗的男性成功率(89%)显著高于接受放疗的男性(56%)。接受AUS翻修术的男性成功率更低(40%),尤其是接受放疗的男性(33%)。
前列腺癌放疗与AUS植入术后显著较低的完全控尿率相关。